Thank you Simpsonly for sharing the excellent DD with the board! The affordability, efficacy and safety put Actipatch at the top of the class versus TENS. Consumers are very savvy, they know a superior product at a great price and sales are going to be astonishing for Actipatch devices.
The opiate epidemic is also going to be a major catalyst to drive Actipatch sales that will come. Will be nice to see life expectancy increase because of Actipatch too!
"The opioid epidemic is pushing down the life expectancy in the US, new research says. Once a leader in longevity, the US has dropped behind most other high-income countries — due in large part to accidental deaths from prescription and illicit opioids that are sweeping the country."
News 
Market Data 
Discover 
